Intra‑tracheal delivery of mesenchymal stem cell‑conditioned medium ameliorates pathological changes by inhibiting apoptosis in asthmatic rats

Asthma, an inflammatory illness of the lungs, remains the most common long-term disease amongst children.
This study tried to elaborate the status of apoptosis in asthmatic pulmonary niche after the application of rat mesenchymal
stem cells (MSC-CM)-derived secretome.
Methods and results Here, we randomly allocated male Wistar rats into three groups (n = 8); Control animals were intratra-
cheally given 50 μl vehicle. In control-matched sensitized rats, 50 μl normal saline was used. In the last group, 50 μl MSC-
CM was applied. Two-week post-administration, transcription of T-bet, GATA-3, Bax, Bcl-2 and Caspase-3 was measured
by gene expression analysis. Pathological injuries were monitored using H&E staining. The BALF level of TNF-α was
measured using ELISA assay. In asthmatic rats received MSC-CM, the expression of T-bet was increased while the level of
GATA-3 decreased compared to the S group (p < 0.05). Levels of BALF TNF-α were suppressed in asthmatic niche after
MSC-CM administration (p < 0.05). Compared to the asthmatic group, MSC-CM had potential to alter the expression of
apoptosis-related genes in which the expression of Bax and Caspase 3 was decreased and the expression of pro-survival
factor, Bcl-2 increased (p < 0.05).
Conclusion Our data notified the potency of direct administration of MSC-CM in the alleviation of airway inflammation,
presumably by down regulating apoptotic death in pulmonary niche